Market News & Trends
ORYZON’s Ladademstat Shows Efficacy Signs in Relapsed SCLC
Oryzon Genomics, S.A. recently presented the first preliminary data from CLEPSIDRA, a Phase 2 trial investigating iadademstat in combination with standard-of-care in relapsing small cell…
ProBioGen Licenses Technology to Bayer
ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, recently announced the closing of a license agreement with Bayer AG…
Flexion Therapeutics & Xenon Pharmaceuticals Announce Acquisition
Flexion Therapeutics, Inc. and Xenon Pharmaceuticals Inc. recently announced the companies have entered into a definitive agreement that provides Flexion with the global rights to…
Novartis Investigational Lung Cancer Therapy Granted FDA Breakthrough Therapy Designation
"We are pleased to announce that the US FDA granted Breakthrough Therapy Designation to capmatinib (INC280) as a first-line treatment for patients with metastatic MET…
Nabriva Therapeutics Earns $5-Million Milestone Payment
Nabriva Therapeutics plc recently announced that Nabriva has earned a $5-million milestone payment under its licensing agreement with Sinovant Sciences related to the U.S. regulatory…
Catalent to Open New Clinical Supply Facility in San Diego
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, recently announced it…
Fate Therapeutics Announces FDA Clearance of IND Application
Fate Therapeutics, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for FT596, the company’s first off-the-shelf chimeric antigen…
Krystal Biotech Announces Initiation of Phase 1/2 Study
Krystal Biotech Inc. recently announced the initiation of the Phase 1/2 study of KB105 in transglutaminase-1 (TGM1) deficient autosomal recessive congenital ichthyosis (ARCI). The study, termed…
Atossa Genetics Announces Completion of Enrollment & Dosing in Phase 1 Clinical Trial
Atossa Genetics Inc. recently announced that all participant activities have been completed in its Phase 1 clinical trial of a new proprietary modified-release oral tablet form…
Innovent & Lilly Set to Transform Diabetes Medication as Clinical Trials Begin
Innovent Biologics, Inc. recently signed a licensing agreement with Eli Lilly and Company (Lilly), one of America’s leading pharmaceutical companies, for the development and potential…